HA
VRTX icon

Harfst & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Harfst & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-476
Closed -$221K – 98
2024
Q3 		$221K Sell
476
-546
-53% -$262K 0.05% 91
2024
Q2 		$479K Hold
1,022
– – 0.11% 80
2024
Q1 		$427K Sell
1,022
-14
-1% -$5.92K 0.1% 85
2023
Q4 		$422K Hold
1,036
– – 0.11% 68
2023
Q3 		$360K Hold
1,036
– – 0.1% 75
2023
Q2 		$365K Sell
1,036
-1,174
-53% -$396K 0.1% 77
2023
Q1 		$696K Sell
2,210
-7
-0.3% -$2.1K 0.2% 74
2022
Q4 		$640K Sell
2,217
-43
-2% -$13.1K 0.18% 76
2022
Q3 		$654K Sell
2,260
-21
-0.9% -$6.04K 0.2% 74
2022
Q2 		$642K Sell
2,281
-22
-1% -$5.89K 0.18% 78
2022
Q1 		$601K Buy
2,303
+405
+21% +$96.1K 0.14% 94
2021
Q4 		$416K Sell
1,898
-1,189
-39% -$231K 0.11% 97
2021
Q3 		$559K Sell
3,087
-109
-3% -$21.3K 0.15% 95
2021
Q2 		$644K Buy
3,196
+78
+3% +$16.3K 0.19% 91
2021
Q1 		$670K Buy
+3,118
New +$685K 0.2% 93

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Harfst & Associates's VRTX Position: Q4 2024 in Review

Harfst & Associates sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 476 shares — an estimated $221K sold.

Harfst & Associates first reported a position in VRTX in Q1 2021 and held it in 15 quarters. The position peaked at $696K in Q1 2023. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Harfst & Associates reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Harfst & Associates sold 476 Vertex Pharmaceuticals shares in Q4 2024, an estimated $221K.
  • Harfst & Associates first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 15 quarters.
  • Harfst & Associates's Vertex Pharmaceuticals position peaked at $696K in Q1 2023.
  • 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Harfst & Associates's 13F filing for Q4 2024, filed 5 Feb 2025.